For this purpose, we prepared a SHP2-deficient cell line using the CRISPR-Cas9 system (Fig. 5a, b), and then added either SHP2WT or different cancer variants for evaluation, measuring phosphorylated-Erk (pErk) levels as a readout of SHP099 inhibitory activity. Here, PTPN11 is linked to cancer.